Talazoparib Plus Enzalutamide Improves OS in mCRPC
The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.
The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.
The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, suggesting imatinib remains the preferred first-line therapy.
The US House of Representatives has recently passed a new legislation that allows patients with cancer and other critical illnesses to receive their medication by…
This event was organised by the European Organisation for Research and Treatment of Cancer (EORTC), the Breast International group (BIG), & the EU Health Pol…
Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.
Today’s podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You…
The National Comprehensive Cancer Network (NCCN; Plymouth Meeting, PA, USA) and the Latin American Cooperative Oncology Group (LACOG; Porto Alegre, Brazil) have renewed their collaboration…
Cancer is a major and worsening global challenge. It is the leading cause of death and disease burden in most countries worldwide, with large inequalities…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
In this studio-based webinar, a multidisciplinary expert panel will address risk-adapted treatment selection after nephrectomy via interactive case discussions on adjuvant therapy in RCC. Expert…
Sewanti Limaye: Proud to contribute to early cancer detection at Sanjeevani / cancer, Datar Cancer, Federal Bank Ltd, OncoDaily, Oncology, R.F. Hospital,